AbbVie Inc.
https://www.abbvie.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbbVie Inc.
Japan Nod For Quizartinib In First-Line AML
Japan’s decision gives quizartinib its first approval globally in specific first-line AML indication, in relatively small but high-need patient population.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.
MDSAP Audit Allows Emerging Firm To Expand Internationally
Blood-collection technology firm Tasso has been recommended for certification by MDSAP. The international qualification is part of a push to offer the company’s technology in countries such as Australia and Canada, CEO Ben Casavant told Medtech Insight.
AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Luminera
- Mavupharma
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice